MedTech Apollo Therapeutics has raised more than £100 million in financing.  

The portfolio-based biopharmaceutical company is rapidly advancing potentially transformative treatments based on breakthrough discoveries.  

The financing was led by Patient Square Capital, which will take a controlling position in the business, with participation from additional investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund.  

Proceeds from the investment will support advancement of Apollo’s robust pipeline into development, expansion of the company’s operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally. 

“Five years ago, Apollo’s innovative model was created by three world-leading universities Cambridge, Imperial College London and University College London forming a joint venture with global pharma partners AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation to efficiently advance breakthrough discoveries that have the potential to be transformative treatments for patients,” said Dr. Richard Mason, CEO of Apollo.  

“In that time, Apollo has exceeded traditional growth benchmarks – rapidly building a pipeline of over 15 promising programs.  

“There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development.  

“We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.” 

Added Jim Momtazee, Managing Partner of Patient Square and member of Apollo’s Board of Directors, added: “For the past twenty years, I have pursued a thesis in therapeutics of backing outstanding teams and building multi-product portfolios in important areas of medicine.  

“Patient Square continues to be very enthusiastic about that business model. We are extremely excited to partner with the team at Apollo, as we see tremendous potential in their product portfolio and their novel partnership approach with three of the world’s top academic institutions pursuing some of the most innovative science globally.  

“We look forward to working closely with the Apollo team to broaden their reach globally and to bring a number of potentially life-changing medicines to patients.”